Crestor Articles
Pfizer drops star drug candidate after DSMB points out excessive mortality in Ph III trial
11 December 2006
Stock Commentary - Europe - week to December 4
11 December 2006
Strong data on AstraZeneca/Shionogi's Crestor head at the AHA
20 November 2006
Shionogi's six-month income drops 23%
20 November 2006
AstraZeneca's offer to Medicare Part D enrollees
20 November 2006
Stock Commentary - Europe - week to Nov 6, 2006
13 November 2006
Japan stock market week to Sept 18, 2006
25 September 2006
Crestor and ezetimibe reduce CRP levels in CD study
11 September 2006
'Statins could slow AAA growth,' US researchers
24 July 2006
Strong combo data for AstraZeneca's Crestor
26 June 2006
Merck & Co's Inegy outperforms Crestor in study
26 June 2006
Shionogi's 2005 sales 196.4B yen, down 1.5%
29 May 2006
Strong data for Crestor with updated guidelines
22 May 2006
Crestor better than Lipitor in Hispanics
3 April 2006
Japan stock market week to March 20, 2006
27 March 2006
Stock Commentary - Europe - week to Mar 13, 2006
20 March 2006
Japan stock market week to Feb 13, 2006
20 February 2006
AstraZeneca's 4th-qtr profit leaps 30% but firm admits thin pipeline
13 February 2006
AstraZeneca profit leaps 30% but firm admits thin pipeline
6 February 2006
AstraZeneca delight at NICE ruling on statins
30 January 2006
Statins account for 81% of first-line dyslipidemia treatment
30 January 2006
Japan stock market week to Dec 5
12 December 2005
Danger to patients from weak US Rx system: CU
12 December 2005
Shionogi's fiscal half-year revenue up 1.6%
12 December 2005
Good 1st-qtr results for Shionogi
22 August 2005
Japan stock market week to August 8
15 August 2005
Astra Zeneca 2nd-qtr pretax profit leaps 67%
8 August 2005
AstraZeneca sees 2nd-qtr pretax profit leap 67%
1 August 2005
French CNMA warns over statin "misuse"
20 June 2005
Japan stock market week to June 6
13 June 2005
Japan stock market week to May 23
30 May 2005
Japan stock market week to May 2
9 May 2005
Japan stock market week to April 25
26 April 2005
AstraZeneca's Crestor 5mg available in EU
25 April 2005
$50,000 million Crestor award
25 April 2005
Stock Commentary - Europe
18 April 2005
Stock Commentary - Europe
14 March 2005
Crestor: 21% cut in CRP in African-Americans
14 March 2005
FDA clears Crestor's labelling revision
7 March 2005
Analysts slash forecasts on AstraZeneca's Crestor
7 March 2005
Shionogi's 3rd-qtr sees sales drop 2.9%
21 February 2005
Stock Commentary - Europe
7 February 2005
AstraZeneca shares up on 16% hike in 2004 pretax profit
31 January 2005
Stock Commentary - Europe
31 January 2005
Japan stock market week to January 24
31 January 2005
Slowdown in revenue growth forecast for AstraZeneca
31 January 2005
AstraZeneca's Exanta hit with setback
24 January 2005
Possible Crestor link with patient death
17 January 2005
Japan stock market week to January 10
17 January 2005
AstraZeneca shares slump as promotion of Iressa is suspended
10 January 2005
Stock Commentary - Europe
20 December 2004
Fresh calls for Crestor's removal
8 November 2004
New Data confirm benefits of AstraZeneca's Crestor in treating broad range of patients
1 November 2004
Tokyo pharma stocks - week to October 25
1 November 2004
AstraZeneca's EPS up 56%, sales rise 10%
1 November 2004
Statins to open door for more US OTC switches?
20 September 2004
Editor's views on AstaZeneca Exanta woes and Bayer/S-P deal
20 September 2004
10M milestone for AstraZeneca's Crestor
13 September 2004
Shionogi profits up on plan, sales decline
23 August 2004
AstraZeneca's Crestor celebrates first year of US approval
16 August 2004
Germany: same price for generic, brand statins?
2 August 2004
AstraZeneca urges FDA on Crestor petition
2 August 2004
AstraZeneca's 2nd-qtr sales jump 19%
2 August 2004
Stock Commentary - Europe
5 July 2004
Stock Commentary - Europe
21 June 2004
EU regulators alter Crestor label
14 June 2004
AstraZeneca warns on high-dose Crestor use
24 May 2004
AstraZeneca's 1st-qtr sales pass $5 billion
3 May 2004
Dual Ezetrol/Zocor therapy effective
3 May 2004
AstraZeneca forecasts good growth in Spain
3 May 2004
AstraZeneca's Crestor is superior to Lipitor in reducing CVD risk factors in diabetics
26 April 2004
$1-$13 million a day at risk from product launch delays
22 March 2004
AstraZeneca's Crestor hold 6.1% of US NRx statins market
22 March 2004
Stock Commentary - Europe
15 March 2004
Public Citizen calls for Crestor ban
15 March 2004
Positive new data for AstraZeneca's Crestor
15 March 2004
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
